In advanced stage mantle cell lymphoma, conventional chemotherapy yields a complete remission rate below 40%, and the median survival rate is only about 3 years. Between 1991 and 1996 we treated nine such patients (six male; three female) with high-dose chemotherapy (six of these also with 12 Gy fractionated total body irradiation (TBI) ) and peripheral stem cell support (n = 8) or allogeneic bone marrow transplantation (n = 1). The median age was 47 years (range, 28-61). At the time of high-dose chemotherapy, five patients were in first complete remission (CR), two in first partial remission (PR) and two in second remission (CR = 1; PR = 1). High-dose chemotherapy included TBI (12 Gy), etoposide and cyclophosphamide (patients 1-5), TBI and cyclophosphamide (patient 7), busulfan, etoposide and cyclophosphamide (patients 6 and 9), cyclophosphamide and busulfan (patient 8). The patterns of toxicity according to the Bearman score were usually mild (mucositis grade 2, n = 7; renal grade I, n = 2) with no therapy-related fatality. Only one patient developed hepatic toxicity grade III (veno-occlusive disease) but recovered completely. The median time to neutrophil engraftment was 10 days (range, 8-15). After high-dose chemotherapy all patients achieved complete remission. After a median follow-up of 22 months (range, 9.4-64) all patients remain in continuous complete remission. These encouraging results suggest that high-dose chemotherapy can be applied safely and leads to longterm disease-free survival in otherwise incurable disease. Keywords: low-grade lymphoma; mantle-cell lymphoma; bone marrow transplantation; peripheral stem cell support Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin's lymphoma, including the formerly designated centrocytic lymphoma according to the Kiel classification 1 and the intermediate lymphocytic and mantle zone lymphomas.
MCL was recently included in the revised EuropeanAmerican classification of lymphoid neoplasms (REAL). 3 According to histopathologic and phenotypic characteristics, MCL represents 2-8% of all non-Hodgkin's lymphomas. 4 The most consistent cytogenetic abnormality in MCL is the translocation t(11;14)(q13;q32). 5 The bcl-1 locus on chromosome 11 is juxtaposed to chromosome 14 within the immunoglobulin heavy chain gene. 6 The translocation has been shown to result in overexpression of the bcl-1 oncogene and deregulation of cyclin D1 which controls the transition from the G1 phase to the S phase of the cell cycle. 7, 8 This lymphoma is most prevalent in male patients over 50 years and includes generalized adenopathies, splenomegaly and stage IV disease. Bone marrow involvement is seen in 75% of the cases and extranodal gastrointestinal involvement in 25%. The median overall survival rate is about 3 years; longer in patients with mantle-zone subtype or localized disease and shorter in patients with blastoid cells. [9] [10] [11] [12] The present work describes the response and outcome of nine patients with advanced MCL undergoing high-dose chemotherapy with or without TBI and peripheral stem cell support or allogenic bone marrow transplantation.
Patients and methods

Patients
Between November 1991 and January 1996, 10 patients diagnosed with centrocytic lymphoma (according to the Kiel classification) in remission after conventional chemotherapy were treated with high-dose chemotherapy with (n = 6) or without (n = 4) TBI. A later pathological review led to a reclassification in one case to a follicular lymphoma. The characteristics of the remaining nine patients are shown in Table 1 : median age 47 years (range 28-61); six males, three females; two patients with marrow involvement; extranodal involvement in four patients (gastrointestinal n = 3; orbita n = 1). Prior to high-dose chemotherapy, seven patients were in first remission (CR = 5, PR = 2) and two in second remission (CR = 1; PR = 1). Induction therapy had consisted of four to six cycles CHOP (patients 1, 3, 4 and 5) or CHOEP (patient 2); one patient (patient 6) had received total nodal irradiation with 30 Gy after four CHOP cycles. Two patients (patients 7 and 8) had received Dexa-BEAM (dexamethasone, BCNU, 
Bu/Cycl/VP16 alloBMT 1922+ ASHAP × 3/involved field HD = high dose; DFS = disease-free survival; TBI = total body irradiation; VP16 = etoposide; Cycl = cyclophosphamide; Bu = busulfan; CR = complete remission; PR = partial remission. a These two patients are also included in the report of Dreger et al. 20 melphalan, etoposide and cytosine-arabinoside) as induction therapy. Salvage therapy after relapse consisted either of two to three ASHAP cycles (doxorubicin, methylprednisone, cytosine-arabinoside, cisplatinum) alone (patient 1), or with a supplemental supra-and infradiaphragmal radiation (patient 9).
The study was approved by the local ethic commission. Informed consent was obtained from each patient.
Failure-free survival (FFS) was defined as the time from treatment to the time of disease progression, last follow-up or death from any cause. Overall survival (OS) was defined as the time from treatment to the time of last follow-up or death from any cause. FFS and OS were calculated by the Kaplan-Meier method. 13 Toxicity was recorded using the grading system described by Bearman et al. 14 
Stem cell source
Peripheral blood stem cells were collected after stimulation with human G-CSF (filgrastim, R-metHug-G-CSF; Amgen, Thousand Oaks, CA, USA) 10 g/kg/BW (n = 6) or 24 g/kg/BW (n = 2). Leukaphereses, using the Fenwal CS 3000 (Baxter Deutschland, Munich, Germany) or the Cobe Spectra (Cobe Laboratories, Lakewood, CO, USA) begun day 5 after stimulation. Up to 10 l of blood per apheresis was processed at a flow rate of 50 to 70 ml/min. A mean volume of 250 ml was collected. The cell suspension was concentrated to a final volume of 50 ml and mixed with the same volume of minimal essential medium (MEM) containing 20% dimethylsulfoxide. The final 100 ml harvest product was transferred into freezing bags and frozen to −100°C with a computer-controlled cryopreservation device. The bags were moved to liquid phase nitrogen and stored at −196°C. After a median of two leukaphereses (range 1-3) a median of 6.45 × 10 
High-dose chemotherapy regimen
The high-dose therapies consisted of regimens based on TBI (12 Gy, fractionated) with cyclophosphamide (120 mg/kg body weight) (patient 7) and etoposide (30-45 mg/kg body weight) (patients 1-5). Patients 6 and 9, who had experienced prior radiation received busulfan (16 mg/kg), cyclophosphamide (120 mg/kg/BW) and etoposide (30-45 mg/kg/BW). The conditioning regimen of patients 7 and 8 who had been pretreated with Dexa-BEAM consisted of cyclophosphamide (120 mg/kg/BW) either with TBI (12 Gy) or busulfan (16 mg/kg/BW) (see Table 1 ).
Results
At a median follow-up period of 22 months (range 9.2-64), all patients are alive and disease-free. Grade II mucositis was seen in all patients, renal toxicity grade I in two. One patient treated with busulfan suffered hepatic toxicity grade III, which fulfilled the criteria for veno-occlusive disease, but symptoms resolved completely within 4 weeks. Eight patients experienced fever of unknown origin (FUO); in the ninth, pneumonia was diagnosed. Post-transplantation hematological recovery was rapid. An absolute neutrophil count (ANC) of 0.5/nl was achieved at a median of 10 days and an unsupported platelet count of 50/nl was achieved after a median of 35 days.
Discussion
Despite growing knowledge about morphology, genetics and clinical spectrum of MCL, guidelines for therapeutic strategies do not exist. In most of the retrospective reports on MCL treatments, the median time to treatment failure is less than 18 months regardless of treatment type. 10 The rate of complete response is below 40% and the median survival rate ranges from 3 to 4 years. 10 In the only prospective study concerning chemotherapy-treatment of MCL, Meuser et al 15 randomized 63 patients with MCL into treatment groups including either CVP (cyclophosphamide, vincristine and prednisone) or CHOP (CVP + doxorubicin). The diseasefree survival was 10 months in the CVP group and 7 months in the CHOP group. The overall survival was 32 and 37 months, respectively. In a retrospective analyses of 36 patients with MCL in SWOG trials, Fisher et al 16 reported a median failure-free survival period of 20.5 months and a median overall survival period of 36 months. In a review of 12 trials with 524 patients with MCL, Press et al 17 found the same failure-free and overall survival rates as in the SWOG trials. In a retrospective multivariate analysis of 65 patients with MCL, Zucca et al 11 found some benefit for anthracycline-treated patients in terms of response and survival. Similar to the other investigations, however, the median survival in their series was only 42 months.
In view of such poor outcomes, our results in terms of remission and survival rate using high-dose chemotherapy in patients with MCL are encouraging. In a similarly small study, Stewart et al 18 treated nine relapsed MCL patients with high-dose chemotherapy and autologous stem cell or bone marrow support. After 2 years, the overall and failurefree survival was 34%. The major difference between that study and ours lies in the pretreatment selection. In the present study all patients were chemosensitive to induction or salvage chemotherapy, leading to at least a partial remission. By means of high-dose chemotherapy, four PRs following induction/salvage therapy were converted into long lasting CRs. Recently, Haas et al 19 published results on treatment of 13 MCL patients with high-dose chemotherapy. One therapy-related fatality was reported. After a median follow-up of 18 months, 10 patients remained disease-free, while two others had relapsed at 10 and 11 months. In a similiar study, Dreger et al 20 reported nine patients with MCL who underwent high-dose chemotherapy. After a median follow-up of 12 months all patients were in continuing clinical remission.
We conclude that since the long-term prognosis of patients with MCL receiving conventional chemotherapy is poor, the timely use of high-dose chemotherapy and autologous stem cell support should be considered for chemosensitive patients in advanced disease. Further studies should investigate the curative potential of high-dose chemotherapy in patients with such an otherwise incurable disease.
